Last reviewed · How we verify
Crizotinib Capsules
Crizotinib is a tyrosine kinase inhibitor that blocks ALK (anaplastic lymphoma kinase) and ROS1 signaling to inhibit cancer cell growth.
Crizotinib is a tyrosine kinase inhibitor that blocks ALK (anaplastic lymphoma kinase) and ROS1 signaling to inhibit cancer cell growth. Used for ALK-positive metastatic non-small cell lung cancer, ROS1-positive metastatic non-small cell lung cancer.
At a glance
| Generic name | Crizotinib Capsules |
|---|---|
| Also known as | Xalkori |
| Sponsor | Shouyao Holdings (Beijing) Co. LTD |
| Drug class | ALK/ROS1 tyrosine kinase inhibitor |
| Target | ALK, ROS1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Crizotinib selectively inhibits ALK and ROS1 receptor tyrosine kinases, which are often aberrantly activated in certain cancers through chromosomal translocations. By blocking these kinases, the drug prevents downstream signaling that drives proliferation and survival of ALK-positive or ROS1-positive tumor cells. This targeted approach is particularly effective in non-small cell lung cancers harboring ALK or ROS1 fusions.
Approved indications
- ALK-positive metastatic non-small cell lung cancer
- ROS1-positive metastatic non-small cell lung cancer
Common side effects
- Vision disorders (blurred vision, diplopia)
- Gastrointestinal toxicity (nausea, vomiting, diarrhea)
- Edema (peripheral, facial)
- Fatigue
- Elevated transaminases
- Bradycardia
Key clinical trials
- A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
- A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases (PHASE3)
- A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer (PHASE3)
- A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC (PHASE3)
- Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (PHASE2)
- A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer (PHASE3)
- A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (PHASE3)
- Safety and Efficacy of Xalkori ROS1
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Crizotinib Capsules CI brief — competitive landscape report
- Crizotinib Capsules updates RSS · CI watch RSS
- Shouyao Holdings (Beijing) Co. LTD portfolio CI